Track topics on Twitter Track topics that are important to you
Product to be sold under market leading ZEPHEX® brand
Tlalnepantla, State of Mexico, January 8, 2015 - Mexichem, S.A.B. de C.V. (BMV: MEXCHEM*) (“the Company” or “Mexichem”) announces that on December 31, 2014, its Mexichem Limited UK Ltd subsidiary, a division of Mexichem’s Fluor Chain, acquired from E.I. Du Pont de Nemours and Company the distribution and sale license for pharmaceutical grade HFC-227ea/P a medical propellant, further strengthening the market leading position of its ZEPHEX® brand.
The product is used to safely deliver a variety of drugs and medications in aerosol form, including use in metered-dose inhalers for treatment of asthma. Under the terms of the acquisition, Mexichem has acquired exclusive global rights to sell and distribute the product for the regulated medical and pharmaceutical propellant market under its ZEPHEX® brand, the global leading brand of medical propellants contained in around 75% of inhalers produced worldwide.
Simon Gardner, General Manager of Mexichem Fluor Medical Products, said: “Since 1995 ZEPHEX® products have filled around 3.5 billion inhalers, helping to improve the lives of over 100 million people every year. This acquisition highlights our continued commitment
to leading the market and will allow us to further support a valuable part of our customer’s product portfolios.”
Mexichem is a global specialty chemical company, producing key raw materials for products used in infrastructure, housing, drinking water and other vital industries. Our clients are located in more than 60 countries and rely on our efficient production to satisfy their needs. At present, the company is focusing on its three key production chains: Chlorine Vinyl (including Resins, compounds and Derivatives and PMV), Integral Solutions and Fluorine. The Company has annual revenues of more than US$ 5 billion, and has been traded on the Mexican Securities Exchange for more than 30 years.
In addition to historical information, this press release contains "forward-looking" statements that reflect management's expectations for the future. A variety of important factors could cause results to differ materially from such statements. These factors are noted throughout Mexichem’s regulatory filings. The forward-looking statements included herein represent Mexichem’s views as of the date of this press release. Mexichem undertakes no obligation to revise or update publicly any forward looking statement for any reason unless required by law.Mexichem Fluor Matt Hicks Global Communications Manager email@example.com +44 (0) 7823 520308NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...